Biopharm group continues efforts in fight against antibiotic resistance through investment

Debiopharm Group, international biopharmaceutical group, has continued its efforts in the fight against antibiotic resistance by investing in antibiotic development through acquiring a minority stake in ABAC Therapeutics.

The drug development company of Debiopharm Group is developing antibiotics based on afabicin (Debio 1450) — a selective antibiotic against Staphylococci — in addition to two earlier stage projects (Debio 1453 and Debio 1454) against multidrug-resistant pathogens among the WHO and CDC priority targets.

ABAC’s, PasNas research platform enables the identification of new targeted molecules and the most advanced programme targets Acinetobacter — which is at the root of multiple difficult to treat infections.

“We are delighted with our investment in ABAC. The main focus of Debiopharm Innovation Fund's investments is smart data, but we also invest in pharmaceutical and diagnostic companies that are strategically important to Debiopharm Group. Just like us, ABAC is tackling antibiotic resistance,” stated Thierry Mauvernay, president of Debiopharm Group.

The investment was made through the company’s innovation fund and strategic investment fund and demonstrates the synergy between the companies in the group to fight antibiotic resistance.